Shanghai Sigma-Audley New Material Technology: difference between revisions

Diff·revision 8 → 9·21:47, 15 Jan 2025

Difference between revision 8 and revision 9 of Shanghai Sigma-Audley New Material Technology. 13 lines changed; the page grew by 1,157 bytes.

Revision 8 — 18:35, 2 Jan 2025 SatietySunniva (talk) add the storage and handling guidance the organisation publishes 5,045 bytes +33	Revision 9 — 21:47, 15 Jan 2025 TallySheetTad (talk) rm the comparison with another supplier; there is no common basis for it 6,202 bytes +1,157
1	{{Infobox organisation	1	{{Infobox organisation
2	\| name = Shanghai Sigma-Audley New Material Technology Co., Ltd.	2	\| name = Shanghai Sigma-Audley New Material Technology Co., Ltd.
+		3	\| image = facility.svg
+		4	\| caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki.
3	\| Legal name = Shanghai Sigma-Audley New Material Technology Co., Ltd.	5	\| Legal name = Shanghai Sigma-Audley New Material Technology Co., Ltd.
4	\| Trading name = SSA	6	\| Trading name = SSA
⋮		⋮
28	Reports reaching this wiki describe vialled lyophilised material with a batch-specific certificate, packaged with a cold pack for the incretin analogues.{{r\|reports}} Packaging descriptions have been consistent enough across submissions to suggest a settled fulfilment process, which is a modest but real observation about an organisation of this type.	30	Reports reaching this wiki describe vialled lyophilised material with a batch-specific certificate, packaged with a cold pack for the incretin analogues.{{r\|reports}} Packaging descriptions have been consistent enough across submissions to suggest a settled fulfilment process, which is a modest but real observation about an organisation of this type.
29		31
+		32	The organisation's own material describes a product range and documentation practice; it makes no certification claim that this wiki has been able to corroborate, and any such claim would in any case require assessment against the applicable framework rather than acceptance at face value.{{r\|gmp,selfpub}}
+		33
+		34	== Product range ==
+		35	\| Class \| Representative listings \| Documentation reported \|
+		36	\|---\|---\|---\|
+		37	\| Incretin analogues \| Semaglutide, tirzepatide, retatrutide \| Batch certificate, HPLC trace \|
+		38	\| Research peptides \| Repair and secretagogue peptides \| Batch certificate \|
+		39	\| SARMs \| Bulk and capsuled \| Certificate with purity; specification sheet on request \|
+		40	\| Injectable oils and raw materials \| Bulk \| Certificate with identity and purity; specification sheet on request \|
+		41
30	== References ==	42	== References ==
31	{{reflist}}	43	{{reflist}}
⋮		⋮
35	<ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref>	47	<ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref>
36	<ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref>	48	<ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref>
+		49	<ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref>
37		50
38	{{DEFAULTSORT:Shanghai Sigma-Audley New Material Technology}}	51	{{DEFAULTSORT:Shanghai Sigma-Audley New Material Technology}}